

# Francesco Spina

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4061898/publications.pdf>

Version: 2024-02-01

24  
papers

602  
citations

686830

13  
h-index

642321

23  
g-index

24  
all docs

24  
docs citations

24  
times ranked

1207  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nilotinib-induced bone marrow CD34+/lin <sup>-</sup> Ph <sup>+</sup> cells early clearance in newly diagnosed CP-chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study. <i>European Journal of Haematology</i> , 2021, 107, 436-448.	1.1	4
2	Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin <sup>-</sup> cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment. <i>PLoS ONE</i> , 2019, 14, e0218444.	1.1	9
3	Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival. <i>Leukemia and Lymphoma</i> , 2019, 60, 101-109.	0.6	7
4	Nilotinib induced bone marrow CD34+/lin <sup>-</sup> Ph <sup>+</sup> cells early clearance in newly diagnosed CP-chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E162-E164.	2.0	4
5	Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 406-409.	2.0	16
6	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. <i>Oncotarget</i> , 2018, 9, 23443-23450.	0.8	12
7	Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin <sup>-</sup> cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment. <i>Cancer Biomarkers</i> , 2017, 21, 41-53.	0.8	3
8	Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients. <i>Blood</i> , 2015, 126, 3937-3937.	0.6	1
9	GEP Analyses of Bone Marrow CD34+/Lin <sup>-</sup> Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment. <i>Blood</i> , 2015, 126, 3645-3645.	0.6	0
10	Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor. <i>Leukemia and Lymphoma</i> , 2014, 55, 331-336.	0.6	25
11	Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide. <i>Leukemia and Lymphoma</i> , 2014, 55, 2032-2037.	0.6	22
12	Serum Thymus and Activation-Regulated Chemokine Level Monitoring May Predict Disease Relapse Detected by PET Scan after Reduced-Intensity Allogeneic Stem Cell Transplantation in Patients with Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1982-1988.	2.0	14
13	Impact of Cytomegalovirus Replication and Cytomegalovirus Serostatus on the Outcome of Patients with B Cell Lymphoma after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 885-890.	2.0	42
14	Bortezomib Plus Dexamethasone Followed by Escalating Donor Lymphocyte Infusions for Patients with Multiple Myeloma Relapsing or Progressing after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 424-428.	2.0	24
15	Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2013, 90, 340-344.	1.1	2
16	Allogeneic stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: impact of patient characteristics and timing of transplant. <i>Leukemia and Lymphoma</i> , 2012, 53, 96-102.	0.6	24
17	Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 617-626.	2.0	75
18	Long-term patterns of humoral and cellular response after vaccination against influenza A (<sc>H</sc>1<sc>N</sc>1) in patients with hematologic malignancies. <i>European Journal of Haematology</i> , 2012, 89, 111-119.	1.1	16

#	ARTICLE	IF	CITATIONS
19	Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. <i>Leukemia and Lymphoma</i> , 2011, 52, 1262-1270.	0.6	11
20	Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. <i>Haematologica</i> , 2009, 94, 654-662.	1.7	62
21	Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. <i>Blood</i> , 2009, 113, 4771-4779.	0.6	69
22	Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. <i>Leukemia and Lymphoma</i> , 2008, 49, 2156-2162.	0.6	143
23	The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Predicts Survival and Non-Relapse Mortality in Lymphoma and Myeloma Patients Undergoing Reduced-Intensity or Non-Myeloablative Allogeneic Stem Cell Transplantations .. <i>Blood</i> , 2008, 112, 2144-2144.	0.6	2
24	Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2007, 92, 418-420.	1.7	15